Natesto
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
CanadaPhone Number
(877) 300-1833Website
www.natesto.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Natesto
Acerus Pharmaceuticals Corporation offers Natesto®, a testosterone replacement therapy designed for adult males suffering from low testosterone levels due to medical conditions such as hypogonadism. The product is administered intranasally using a simple applicator, providing a convenient and effective method for raising testosterone levels while minimizing the risk of reducing the body's own testosterone production. Natesto aims to alleviate symptoms associated with low testosterone, including fatigue and reduced libido, and is not approved for age-related testosterone deficiency. The company targets adult males who require testosterone therapy for medical reasons, ensuring a focus on safety and efficacy through clinical trials.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Natesto your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Natesto, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Natesto had a recent Job posting/layoffs
Earning: See what the market has to say on Natesto recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Natesto
Funding: Get notified immidiatlly once Natesto has new funding data
Check out if Natesto is spiking on competitors!
Check if Natesto has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Natesto launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Natesto
Compare insights from companies similar to Natesto, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Natesto
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Natesto is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Natesto is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Natesto.
Natesto Tech Stack
A closer look at the technologies used by Natesto
See more technologies
Natesto News & Media
Expanded U.S. NATETSO® Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the revised commercial partnership agreement with Aytu Bioscience (“Aytu”) to accelerate the growth of NATESTO® in the United States is now closed and fully effective as of December 1, 2019. Both parties have mutually waived the closing conditions of the revised partnership agreement, including the requirement that Acerus complete a raise of a minimum of USD 10 million on or before the end oAcerus Provides Update on Temporary Unavailability of NATESTO® in Canada and South Korea
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today provided an update on the temporary unavailability of NATESTO® in Canada and South Korea, following the previous announcement of the voluntary replacement of certain NATESTO® lots released on the Canadian and South Korean markets. Acerus made minor modifications to the manufacturing process that appear to have resolved the previously identified issues and has produced a batch of NATESTO® (the “Revised BatcAcerus Pharma Hosting Key Opinion Leader Meeting on Unique Clinical Evidence of NATESTO® for Treatment of Hypogonadism
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced it will host a Key Opinion Leader (KOL) meeting on new, unique clinical evidence supporting the expanded use of NATESTO® for the treatment of hypogonadism on Wednesday, October 30th in New York City. The event will feature a presentation by KOL Dr. Ranjith Ramasamy, MD, University of Miami, who will discuss the current treatment landscape, unmet medical need, and new clinical evidence for men witNew Data Demonstrates That NATESTO® Increases Serum Testosterone and Improves Symptoms While Maintaining Normal Semen Parameters in Men With Low Testosterone Through Six Months
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO® Spermatogenesis Study as part of the “Late Breaking” Abstract Session at the 75th Annual American Society for Reproductive Medicine (ASRM) Scientific Conference in Philadelphia, PA. Yesterday’s presentation was one of only six abstracts accepted as part of this session. Findings from the study demonstrated that 95% of men treated with NATESTO® for hypogo
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Natesto
Sign Up For FreeTo access detailed company insights
Acerus Pharmaceuticals Corporation offers Natesto®, a testosterone replacement therapy designed for adult males suffering from low testosterone levels due to medical conditions such as hypogonadism. The product is administered intranasally using a simple applicator, providing a convenient and effective method for raising testosterone levels while m... Read More
